Logo image of ACLX

ARCELLX INC (ACLX) Stock Fundamental Analysis

NASDAQ:ACLX - US03940C1009 - Common Stock

69.35 USD
-0.55 (-0.79%)
Last: 8/28/2025, 1:52:05 PM
Fundamental Rating

3

ACLX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 547 industry peers in the Biotechnology industry. While ACLX has a great health rating, there are worries on its profitability. ACLX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ACLX has reported negative net income.
ACLX had a negative operating cash flow in the past year.
In the past 5 years ACLX always reported negative net income.
In the past 5 years ACLX reported 4 times negative operating cash flow.
ACLX Yearly Net Income VS EBIT VS OCF VS FCFACLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

The Return On Assets of ACLX (-30.37%) is better than 66.73% of its industry peers.
ACLX's Return On Equity of -47.93% is fine compared to the rest of the industry. ACLX outperforms 66.36% of its industry peers.
Industry RankSector Rank
ROA -30.37%
ROE -47.93%
ROIC N/A
ROA(3y)-27.93%
ROA(5y)-37.97%
ROE(3y)-43.4%
ROE(5y)-50.37%
ROIC(3y)N/A
ROIC(5y)N/A
ACLX Yearly ROA, ROE, ROICACLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

ACLX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACLX Yearly Profit, Operating, Gross MarginsACLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

7

2. Health

2.1 Basic Checks

ACLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACLX has been increased compared to 1 year ago.
The number of shares outstanding for ACLX has been increased compared to 5 years ago.
The debt/assets ratio for ACLX has been reduced compared to a year ago.
ACLX Yearly Shares OutstandingACLX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ACLX Yearly Total Debt VS Total AssetsACLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ACLX has an Altman-Z score of 8.48. This indicates that ACLX is financially healthy and has little risk of bankruptcy at the moment.
ACLX has a Altman-Z score of 8.48. This is amongst the best in the industry. ACLX outperforms 84.10% of its industry peers.
There is no outstanding debt for ACLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.48
ROIC/WACCN/A
WACC9.72%
ACLX Yearly LT Debt VS Equity VS FCFACLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 3.81 indicates that ACLX has no problem at all paying its short term obligations.
ACLX's Current ratio of 3.81 is in line compared to the rest of the industry. ACLX outperforms 43.69% of its industry peers.
A Quick Ratio of 3.81 indicates that ACLX has no problem at all paying its short term obligations.
With a Quick ratio value of 3.81, ACLX perfoms like the industry average, outperforming 46.07% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.81
Quick Ratio 3.81
ACLX Yearly Current Assets VS Current LiabilitesACLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

ACLX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -228.85%.
Looking at the last year, ACLX shows a very negative growth in Revenue. The Revenue has decreased by -60.64% in the last year.
EPS 1Y (TTM)-228.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.31%
Revenue 1Y (TTM)-60.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-72.41%

3.2 Future

Based on estimates for the next years, ACLX will show a very strong growth in Earnings Per Share. The EPS will grow by 24.93% on average per year.
ACLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.17% yearly.
EPS Next Y-106.46%
EPS Next 2Y-33.54%
EPS Next 3Y-11.83%
EPS Next 5Y24.93%
Revenue Next Year-59.75%
Revenue Next 2Y5.05%
Revenue Next 3Y29.65%
Revenue Next 5Y42.17%

3.3 Evolution

ACLX Yearly Revenue VS EstimatesACLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ACLX Yearly EPS VS EstimatesACLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACLX. In the last year negative earnings were reported.
Also next year ACLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACLX Price Earnings VS Forward Price EarningsACLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACLX Per share dataACLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

ACLX's earnings are expected to decrease with -11.83% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.54%
EPS Next 3Y-11.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACLX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCELLX INC

NASDAQ:ACLX (8/28/2025, 1:52:05 PM)

69.35

-0.55 (-0.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-18 2025-11-18/amc
Inst Owners96.7%
Inst Owner Change-2.9%
Ins Owners2.31%
Ins Owner Change4.21%
Market Cap3.85B
Analysts85.6
Price Target115.33 (66.3%)
Short Float %14.55%
Short Ratio12.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-18.41%
Min EPS beat(2)-46.25%
Max EPS beat(2)9.43%
EPS beat(4)1
Avg EPS beat(4)-24.54%
Min EPS beat(4)-51.89%
Max EPS beat(4)9.43%
EPS beat(8)4
Avg EPS beat(8)12.62%
EPS beat(12)4
Avg EPS beat(12)-25.07%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-52.93%
Min Revenue beat(2)-60.26%
Max Revenue beat(2)-45.6%
Revenue beat(4)0
Avg Revenue beat(4)-43.51%
Min Revenue beat(4)-60.26%
Max Revenue beat(4)-25.74%
Revenue beat(8)3
Avg Revenue beat(8)27.83%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.23%
PT rev (3m)-2.02%
EPS NQ rev (1m)2.01%
EPS NQ rev (3m)-26.2%
EPS NY rev (1m)0.72%
EPS NY rev (3m)-0.53%
Revenue NQ rev (1m)-23.33%
Revenue NQ rev (3m)-57.06%
Revenue NY rev (1m)-29.21%
Revenue NY rev (3m)-30.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 67.5
P/FCF N/A
P/OCF N/A
P/B 9.81
P/tB 9.81
EV/EBITDA N/A
EPS(TTM)-3.42
EYN/A
EPS(NY)-3.57
Fwd EYN/A
FCF(TTM)-2.22
FCFYN/A
OCF(TTM)-2.13
OCFYN/A
SpS1.03
BVpS7.07
TBVpS7.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.37%
ROE -47.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.93%
ROA(5y)-37.97%
ROE(3y)-43.4%
ROE(5y)-50.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80.04%
Cap/Sales 8.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.81
Quick Ratio 3.81
Altman-Z 8.48
F-Score2
WACC9.72%
ROIC/WACCN/A
Cap/Depr(3y)494.02%
Cap/Depr(5y)435.82%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-228.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.31%
EPS Next Y-106.46%
EPS Next 2Y-33.54%
EPS Next 3Y-11.83%
EPS Next 5Y24.93%
Revenue 1Y (TTM)-60.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-72.41%
Revenue Next Year-59.75%
Revenue Next 2Y5.05%
Revenue Next 3Y29.65%
Revenue Next 5Y42.17%
EBIT growth 1Y-165.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-104.18%
EBIT Next 3Y7.93%
EBIT Next 5Y22.46%
FCF growth 1Y-217.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-202.59%
OCF growth 3YN/A
OCF growth 5YN/A